Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Top Cited Papers
- 1 February 2019
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (2) , 282-296
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
This publication has 36 references indexed in Scilit:
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular CarcinomaCancer Research, 2008
- Assessment of Patient-Reported Clinical Outcome in Pancreatic and Other Hepatobiliary CancersJournal of Pain and Symptom Management, 2002
- Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging systemCancer, 2002
- Clinical Characteristics and Prognosis of Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2000
- A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patientsHepatology, 1998